

Disease control and treatment satisfaction in patients with chronic spontaneous urticaria in Japan

Table S1. Currently treated comorbidities in the study cohort

Item, ¹ n (%)	Study cohort (N = 529)
Allergic conditions	
<i>Allergic rhinitis</i>	143 (27.0)
<i>Atopic dermatitis</i>	95 (18.0)
<i>Allergic contact dermatitis</i>	58 (11.0)
<i>Allergic conjunctivitis</i>	47 (8.9)
<i>Bronchial asthma</i>	43 (8.1)
<i>Food allergy</i>	42 (7.9)
<i>Chronic sinusitis</i>	40 (7.6)
<i>Drug allergy</i>	13 (2.5)
<i>Eosinophilic esophagitis</i>	4 (0.8)
<i>Eosinophilic gastroenteritis</i>	3 (0.6)
Lifestyle-related diseases	
<i>Hypertension</i>	84 (15.9)
<i>Hyperlipidemia</i>	50 (9.5)
<i>Diabetes</i>	24 (4.5)
<i>Osteoporosis</i>	12 (2.3)
Psychological disorders	
<i>Insomnia</i>	57 (10.8)
<i>Depression</i>	44 (8.3)
<i>Anxiety</i>	32 (6.0)
Autoimmune disorders	
<i>Thyroid disease</i>	23 (4.3)

<i>Alopecia areata</i>	15 (2.8)
<i>Rheumatoid arthritis</i>	15 (2.8)
<i>Ulcerative colitis</i>	12 (2.3)
<i>Other collagen diseases</i>	9 (1.7)
<i>Crohn's disease</i>	3 (0.6)
<i>Not being treated for any of the above</i>	209 (39.5)

1—Patients could choose more than one response.




Figure S1. Summary of scores in all patients and in subgroups based on UCT for DLQI sub-item scores. * $p < 0.01$ across UCT subgroups (Kruskal–Wallis test); †† $p < 0.01$ vs. UCT 0–7 subgroup (Steel–Dwass test); ‡‡ $p < 0.01$ vs. UCT 8–11 subgroup (Steel–Dwass test). Abbreviations: DLQI—Dermatology Life Quality Index; SD—standard deviation; UCT—Urticaria Control Test